Home › Compare › GEECF vs ABBV
GEECF yields 2000000.00% · ABBV yields 3.06%● Live data
📍 GEECF pulled ahead of the other in Year 1
Combined, GEECF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GEECF + ABBV for your $10,000?
Global Environmental Energy Corp. engages in alternative energy sources, environmental infrastructure, electrical micro-power generation and liquid fuel production. The company also develops and commercializes various technologies in the waste to energy sector, including electrical power generation and liquid fuel production. It offers Biosphere Process System, a waste to energy system that provides solutions for the conversion of waste materials, which includes municipal solid waste, agricultural or forestry surpluses or wastes, industrial or medical waste materials, and traditional fossil fuels in a process that includes automatic separation of metals and plastics, the formation of organic compost, and the heating of the organic residue left from the separation process to high temperatures in a separate chamber, which is deprived of oxygen. The company sells and operates Biosphere Systems in Asia, Europe, the Americas, and the Philippines. Global Environmental Energy Corp. was formerly known as Life Energy & Technology Holdings, Inc. and changed its name to Global Environmental Energy Corp. in Septmber, 2004. The company is based in Nassau, Bahamas. On June 5, 2007, the voluntary petition of Global Environmental Energy Corp. for reorganization under Chapter 11 was converted to Chapter 7. The Company had filed for Chapter 11 bankruptcy on May 19, 2005.
Full GEECF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.